ProPhase Labs (PRPH) Stock Price, News & Analysis

Company Overview

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Key Stats

• Today's Range: $0.41 to $0.47
• 50-Day Range: $0.45 to $0.88
• 52-Week Range: $0.41 to $7.48
• Volume: 199,830 shs
• Average Volume: 405,010 shs
• Market Capitalization: $10.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.00
• Consensus Rating: Buy

ProPhase Labs Stock Analysis - MarketRank™

ProPhase Labs scored higher than 73% of companies evaluated by MarketBeat, and ranked 298th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

ProPhase Labs has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

ProPhase Labs has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ProPhase Labs are expected to grow in the coming year, from ($1.23) to ($0.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ProPhase Labs is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ProPhase Labs is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ProPhase Labs has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.41% of the outstanding shares of ProPhase Labs have been sold short.

Short Interest Ratio / Days to Cover

ProPhase Labs has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ProPhase Labs has recently decreased by 10.53%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ProPhase Labs does not currently pay a dividend.

Dividend Growth

ProPhase Labs does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.41% of the outstanding shares of ProPhase Labs have been sold short.

Short Interest Ratio / Days to Cover

ProPhase Labs has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ProPhase Labs has recently decreased by 10.53%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.26

News Sentiment

ProPhase Labs has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for ProPhase Labs this week, compared to 1 article on an average week.

Search Interest

2 people have searched for PRPH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added ProPhase Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ProPhase Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.70% of the stock of ProPhase Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 9.45% of the stock of ProPhase Labs is held by institutions.

PRPH Stock Analysis - Frequently Asked Questions

How have PRPH shares performed this year?

ProPhase Labs' stock was trading at $0.7571 at the beginning of the year. Since then, PRPH shares have decreased by 39.2% and is now trading at $0.46.
View the best growth stocks for 2025 here.

How were ProPhase Labs' earnings last quarter?

ProPhase Labs, Inc. (NASDAQ:PRPH) released its quarterly earnings results on Thursday, May, 9th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.21. The company had revenue of $3.63 million for the quarter, compared to analysts' expectations of $9.86 million. ProPhase Labs had a negative trailing twelve-month return on equity of 62.92% and a negative net margin of 217.64%.

Who are ProPhase Labs' major shareholders?

ProPhase Labs' top institutional shareholders include Sheets Smith Wealth Management (0.87%).
View institutional ownership trends.

How do I buy shares of ProPhase Labs?

Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ProPhase Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ProPhase Labs investors own include Meta Platforms (META), Pfizer (PFE), Valero Energy (VLO), CymaBay Therapeutics (CBAY), Catalyst Pharmaceuticals (CPRX) and Energy Transfer (ET).

Company Calendar

• Last Earnings: 5/09/2024
• Today: 1/28/2025
• Next Earnings (Estimated): 3/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PRPH
• CUSIP: N/A
• CIK: 868278
• Web: www.prophaselabs.com
• Phone: (215) 345-0919
• Fax: 215-345-5920
• Employees: 130
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $11.00
• High Stock Price Target: $11.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +2,291.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-16,780,000.00
• Net Margins: -217.64%
• Pretax Margin: -298.21%
• Return on Equity: -62.92%
• Return on Assets: -30.22%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 1.47
• Quick Ratio: 1.33

Sales & Book Value

• Annual Sales: $44.38 million
• Price / Sales: 0.25
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.74 per share
• Price / Book: 0.17

Miscellaneous

• Outstanding Shares: 23,870,000
• Free Float: 18,932,000
• Market Cap: $10.98 million
• Optionable: Optionable
• Beta: -0.30